80 related articles for article (PubMed ID: 2226266)
1. [Dextran-ferrite distribution in the body of animals in a nonuniform permanent magnetic field].
Syrkin AB; Iushkov SF; Bulychev IuN; Brusentsov NA; Osipov NE; Karamanov SA; Kolesnikova EIu
Eksp Onkol; 1990; 12(5):71-3. PubMed ID: 2226266
[TBL] [Abstract][Full Text] [Related]
2. Magnetic drug targeting--biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment.
Alexiou C; Jurgons R; Schmid RJ; Bergemann C; Henke J; Erhardt W; Huenges E; Parak F
J Drug Target; 2003 Apr; 11(3):139-49. PubMed ID: 13129824
[TBL] [Abstract][Full Text] [Related]
3. Magnetic targeting after femoral artery administration and biocompatibility assessment of superparamagnetic iron oxide nanoparticles.
Ma HL; Qi XR; Ding WX; Maitani Y; Nagai T
J Biomed Mater Res A; 2008 Mar; 84(3):598-606. PubMed ID: 17618488
[TBL] [Abstract][Full Text] [Related]
4. [Oral iron administration through drinking water as compared with parenteral administration of iron dextran preparations in piglets].
Meyer P; Matzke P; Peschke W; Kaufmann G
Berl Munch Tierarztl Wochenschr; 1975 Nov; 88(21):409-12. PubMed ID: 1200962
[No Abstract] [Full Text] [Related]
5. Locoregional cancer treatment with magnetic drug targeting.
Alexiou C; Arnold W; Klein RJ; Parak FG; Hulin P; Bergemann C; Erhardt W; Wagenpfeil S; Lübbe AS
Cancer Res; 2000 Dec; 60(23):6641-8. PubMed ID: 11118047
[TBL] [Abstract][Full Text] [Related]
6. MRI measurement of regional lung deposition in mice exposed nose-only to nebulized superparamagnetic iron oxide nanoparticles.
Martin AR; Thompson RB; Finlay WH
J Aerosol Med Pulm Drug Deliv; 2008 Dec; 21(4):335-42. PubMed ID: 18800881
[TBL] [Abstract][Full Text] [Related]
7. [Magnetically-guided anesthetics based on highly dispersed iron powders coated by polyacrylamide].
Kurbatova GT; Fedorenko OM; Sokhov ST; Verkholomova IA; Shklovskaia NI
Biofizika; 2002; 47(2):331-7. PubMed ID: 11969173
[TBL] [Abstract][Full Text] [Related]
8. [Parenteral iron replacement].
Cynke E
Praxis (Bern 1994); 1997 May; 86(20):835-6. PubMed ID: 9312810
[No Abstract] [Full Text] [Related]
9. Bioinorganic transformations of liver iron deposits observed by tissue magnetic characterisation in a rat model.
Gutiérrez L; Lázaro FJ; Abadía AR; Romero MS; Quintana C; Puerto Morales M; Patiño C; Arranz R
J Inorg Biochem; 2006 Nov; 100(11):1790-9. PubMed ID: 16899298
[TBL] [Abstract][Full Text] [Related]
10. Comparative toxicity and cell-tissue distribution study on nanoparticular iron complexes using avian embryos and HepG2-cells.
Roth S; Langguth P; Spicher K; Enzmann H
Transl Res; 2008 Jan; 151(1):36-44. PubMed ID: 18061126
[TBL] [Abstract][Full Text] [Related]
11. [Antineoplastic activity of combinations of cytostatics and dextran-ferrite administered to mice with leukemia P-388].
Brusentsov NA; Glazkova TIu; Iavorskaia NP; Iurchenko NIa
Eksp Onkol; 1990; 12(6):59-60. PubMed ID: 2261881
[TBL] [Abstract][Full Text] [Related]
12. Reactivity of iron compounds.
Geisser P
Am J Kidney Dis; 2003 Nov; 42(5):1103-4. PubMed ID: 14582056
[No Abstract] [Full Text] [Related]
13. Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: a comparative study between iron sucrose and iron dextran.
Malindretos P; Sarafidis PA; Rudenco I; Raptis V; Makedou K; Makedou A; Grekas DM
Am J Nephrol; 2007; 27(6):572-9. PubMed ID: 17804904
[TBL] [Abstract][Full Text] [Related]
14. Drug-loaded superparamagnetic iron oxide nanoparticles for combined cancer imaging and therapy in vivo.
Yu MK; Jeong YY; Park J; Park S; Kim JW; Min JJ; Kim K; Jon S
Angew Chem Int Ed Engl; 2008; 47(29):5362-5. PubMed ID: 18551493
[No Abstract] [Full Text] [Related]
15. Ferrite particles: a new magnetic resonance imaging contrast agent. Lack of acute or chronic hepatotoxicity after intravenous administration.
Bacon BR; Stark DD; Park CH; Saini S; Groman EV; Hahn PF; Compton CC; Ferrucci JT
J Lab Clin Med; 1987 Aug; 110(2):164-71. PubMed ID: 3598345
[TBL] [Abstract][Full Text] [Related]
16. Bioequivalence decision for nanoparticular iron complex drugs for parenteral administration based on their disposition.
Schnorr J; Fütterer S; Spicher K; Catarinolo M; Schlösser C; Enzmann H; Langguth P
Regul Toxicol Pharmacol; 2018 Apr; 94():293-298. PubMed ID: 29454888
[TBL] [Abstract][Full Text] [Related]
17. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran?
Sav T; Tokgoz B; Sipahioglu MH; Deveci M; Sari I; Oymak O; Utas C
Ren Fail; 2007; 29(4):423-6. PubMed ID: 17497463
[TBL] [Abstract][Full Text] [Related]
18. Iron oxide nanoparticles for sustained delivery of anticancer agents.
Jain TK; Morales MA; Sahoo SK; Leslie-Pelecky DL; Labhasetwar V
Mol Pharm; 2005; 2(3):194-205. PubMed ID: 15934780
[TBL] [Abstract][Full Text] [Related]
19. Iron overload detection in rats by means of a susceptometer operating at room temperature.
Marinelli M; Gianesin B; Avignolo C; Minganti V; Parodi S
Phys Med Biol; 2008 Dec; 53(23):6849-60. PubMed ID: 19001693
[TBL] [Abstract][Full Text] [Related]
20. Absorption of iron dextran from the peritoneal cavity of rats.
Suzuki K; Twardowski ZJ; Nolph KD; Khanna R; Moore HL
Adv Perit Dial; 1995; 11():57-9. PubMed ID: 8534738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
